Cambium Bio Ltd
AASX:CMB0.45
AUD
0.00
(0.00%)
ISIN
AU0000327769
Return %
Stock
S&P 500
1Y
-6.25
14.20
3Y
-35.71
81.12
5Y
-94.08
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Karolis Rosickas
- Full Time Employees
- 2
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Unit 2.06/31 Lexington Dr Bella Vista NSW Australia 2153
- IPO Date
- Sep 19, 2013
- Website
- cambium.bio
- Similar Companies
- Business
- Cambium Bio Limited is a clinical-stage regenerative medicine company focused on ophthalmology and tissue regeneration. The company leverages a platelet lysate–based platform to develop biologics and cell-based therapies, with a pipeline spanning ocular and musculoskeletal indications. Its lead asset, Elate Ocular®, targets dry eye disease, while Progenza™ represents a stem cell platform aimed at knee osteoarthritis and broader tissue repair applications; additional programs include Sygenus for wound healing indications. Cambium Bio operates primarily in Australia, with headquarters in Paddington, New South Wales, and maintains a pipeline-oriented strategy to advance late-stage assets through clinical development toward commercialisation. The company was founded in 2013 and is listed on the ASX (ticker: CMB), reflecting its governance as an Australian biotechnology company focused on regenerative medicine. Cambium Bio’s corporate activities include early and late-stage financing rounds to support clinical development and expanded partnerships; notably, a strategic capital raise in December 2024 supports Phase 3 progression of Elate Ocular® and broader pipeline advancement. The company’s geographic footprint includes operations in Australia with development activities and potential collaborations across international markets as it pursues regulatory approvals and commercial strategies for its ophthalmology and tissue regeneration programs. Subsidiaries or related entities are aligned with Cambium Bio’s parent structure and its upstream asset development platforms, including Progenza and related biologics initiatives. Cambium Bio targets partnerships with biotech and medical research organizations, clinical research collaborators, and strategic investors to advance its regenerative medicine portfolio and expand its commercial and clinical reach.